Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(1.69)
# 3,308
Out of 5,072 analysts
10
Total ratings
77.78%
Success rate
-2.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Assumes: Overweight | $154 | $128.72 | +19.64% | 1 | Nov 24, 2025 | |
| KRRO Korro Bio | Downgrades: Neutral | n/a | $5.52 | - | 1 | Nov 13, 2025 | |
| XNCR Xencor | Maintains: Overweight | $40 → $42 | $17.38 | +141.66% | 2 | Nov 6, 2025 | |
| INVA Innoviva | Maintains: Overweight | $29 → $31 | $21.71 | +42.79% | 2 | Nov 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $3.62 | +93.37% | 1 | Oct 2, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $39 → $40 | $21.59 | +85.27% | 1 | Aug 1, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $52 | $4.02 | +1,193.53% | 1 | Jul 11, 2025 | |
| HROW Harrow | Initiates: Overweight | $76 | $41.30 | +84.02% | 1 | Jul 11, 2025 |
Belite Bio
Nov 24, 2025
Assumes: Overweight
Price Target: $154
Current: $128.72
Upside: +19.64%
Korro Bio
Nov 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $5.52
Upside: -
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40 → $42
Current: $17.38
Upside: +141.66%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $31
Current: $21.71
Upside: +42.79%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $3.62
Upside: +93.37%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $39 → $40
Current: $21.59
Upside: +85.27%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $4.02
Upside: +1,193.53%
Harrow
Jul 11, 2025
Initiates: Overweight
Price Target: $76
Current: $41.30
Upside: +84.02%